Dataset for Mathematical Model of in vitro Hepatocellular Cholesterol and Lipoprotein Metabolism, fig. 6
Yuri M. Efremov, Anastasia V. Ermolaeva · Figshare · 2022
A simulation showing the effect of anti-PCSK9 antibodies therapy. Here antibodies were applied at the zero time point at different concentrations. Initial concentration of PCSK9 is $10^{14}$ molec./mL. The binding of PCSK9 with antibodies prevents its binding with LDLR and leads to the decrease in LDL/VLDL levels.